Karydas Daphne 4
4 · Mineralys Therapeutics, Inc. · Filed Nov 13, 2025
Insider Transaction Report
Form 4
Karydas Daphne
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-13$10.20/sh+15,000$153,000→ 15,000 total - Sale
Common Stock
2025-11-13$45.81/sh−10,115$463,351→ 4,885 total - Sale
Common Stock
2025-11-13$46.36/sh−4,885$226,446→ 0 total - Exercise/Conversion
Stock Option
2025-11-13−15,000→ 17,900 totalExercise: $10.20Exp: 2035-02-13→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The stock option vests in 12 monthly installments following the date of grant.